20-F: C21 Investments Reports Fiscal 2024 Results, Highlights Strategic Growth

C21 Investments Inc. announces its fiscal year 2024 financial results, showcasing strategic initiatives and expansion in the Nevada cannabis market.

Summary

• C21 Investments Inc. reported a 2% decrease in revenue for fiscal year 2024, totaling $28.3 million, attributed to industry trends post-pandemic.
• Gross profit decreased from 46% to 39% due to weakening product demand and increased supply.
• Income from operations fell by 62% to $1.5 million, primarily due to the decline in gross profit.
• The company completed the acquisition of a new retail dispensary in South Reno, Nevada, for $3.5 million, funded by cash and a private placement.
• A private placement of C$4 million was closed, issuing convertible debentures to fund the dispensary acquisition.
• The company fully repaid the $30 million secured promissory note to its President and CEO, Sonny Newman.
• The company terminated a lease-to-own arrangement in Southern Oregon, receiving $500,000 for two cannabis licenses.
• The company's Nevada cultivation facility expansion was completed, doubling annual production capacity to 8,100 pounds of cannabis flower.
• The company's net loss from discontinued operations was $81,817.
• The company's adjusted EBITDA was $4.5 million.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While there are positive developments like the new dispensary acquisition and debt repayment, the declining revenue and profitability metrics raise concerns. The sentiment is neutral, reflecting both positive and negative aspects.

Positives

• The company completed the acquisition of a new retail dispensary in South Reno, Nevada, expanding its retail footprint.
• The company fully repaid the $30 million secured promissory note to its President and CEO, Sonny Newman, increasing financial flexibility.
• The company's Nevada cultivation facility expansion was completed, doubling annual production capacity.
• The company's wholesale sales increased to $3.0 million during the year ended January 31, 2024.
• The company's adjusted EBITDA was $4.5 million.

Negatives

• The company reported a 2% decrease in revenue for fiscal year 2024, totaling $28.3 million.
• Gross profit decreased from 46% to 39% due to weakening product demand and increased supply.
• Income from operations fell by 62% to $1.5 million, primarily due to the decline in gross profit.
• The company has a working capital deficiency of $6,922,786.
• The company has an accumulated deficit of $72,776,997.

Risks

• Cannabis remains illegal under U.S. federal law, posing regulatory and legal risks.
• The company may face difficulties accessing banking services and processing credit card payments.
• The company's operations are subject to heightened scrutiny by regulators and stock exchanges.
• The company may face unfavorable publicity or consumer perception of cannabis.
• The company's business premises are a target for theft.
• The company may not be able to meet its obligations as they become due, and the Company may require additional funding to continue as a going concern.
• The company is subject to Section 280E of the Code, which may adversely impact the Company and cause it to be subject to higher effective U.S. federal income tax rates than similar companies in other industries.

Future Outlook

The Company's strategic initiatives over the next 12 months include extending our Nevada retail footprint where we have a proven track record of success, continuing our disciplined approach to growth and financing, and internally producing product to expand our Nevada retail footprint.

Management Comments

• President and CEO of C21, Sonny Newman commented: 'With the dispensary's desirable location in a high traffic, flourishing area of South Reno, we anticipate strong revenue growth from this acquisition, along with the added benefit of allowing us to expand the portion of our cultivation capacity sold through our retail channel.'

Industry Context

The reported financial results reflect broader industry trends, including weakening demand and increased supply in cannabis markets, particularly in wholesale, leading to price compression.

Comparison to Industry Standards

• According to Headset, a cannabis industry market analysis site, Nevada cannabis sales have dropped by 6% over the same 12 months ending January 31, 2024.
• According to a recent study by Marijuana Business Daily, legal sales of marijuana are expected to reach $38 billion by the end of 2024, a 12% increase over 2023's total of $34 billion.

Management Changes

Legal Proceedings

• The Company is involved in ongoing litigation related to the EFF purchase agreement, with a trial scheduled for November 2024.
• The Company has filed a motion to recover costs and attorney fees in the Oregon Action, with a hearing scheduled for July 29, 2024.

Related Party Transactions

• The Company made payments totaling $2.03 million to Sonny Newman, the President and Chief Executive Officer of the Company in connection with the Newman Note.
• The Company entered into cancelation agreements with the majority of the Swell Vendors who had rights to Swell Earn-Out shares, canceling those rights for a one-time cash payment.
• The Company has a Consulting Services Agreement with CB1, a Delaware limited liability company, for strategic and business development advice.

Stakeholder Impact

• Shareholders may experience dilution from future financings.
• The Company's ability to service its debt depends on sustaining the profitability of its operations and obtaining sufficient financing on acceptable terms.
• The Company's operations are subject to environmental regulation in the various jurisdictions in which it operates, which may adversely affect the Company's operations.

Next Steps

• Extend Nevada retail footprint.
• Continue disciplined approach to growth and financing.
• Internally produce product to expand Nevada retail footprint.

Key Dates

Keywords

cannabis, Nevada, dispensary, cultivation, retail, revenue, EBITDA, acquisition, legalization, financials